The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.

Combatting Future Viral Threats with Vaccine Advances

More technologies and treatments are emerging for COVID-19—along with new variants.

What’s Next for COVID-19 Vaccines and Variants?

Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.

Key Elements for Assay Transfer Success

Topic

Articles

Pfizer and BioNTech’s request would make them the first vaccine accessible to individuals under the age of 12.

Pfizer, BioNTech Request EUA for COVID-19 Vaccine in Children Aged 5-11

The agency’s human medicines committee approved an additional site in West Point, Pa. in the United States for the manufacture of Janssen’s COVID-19 vaccine. 

EMA Approves Manufacturing Site for Janssen COVID-19 Vaccine

The agency has concluded that an extra dose of the COVID-19 vaccines may be given to those individuals with severely weakened immune systems.

EMA Recommends Boosters of Pfizer and Moderna COVID-19 Vaccines for Some Individuals

The agency received a marketing authorization application a monoclonal antibody treatment for COVID-19 patients.

Application for COVID-19 Treatment Submitted to EMA 

The test developed by Luas Diagnostics and Bond Digital uses a smartphone app to enhance a 15-minute COVID-19 immunity test.

Luas Diagnostics Partners with Bond Digital Health to Launch Enhanced COVID-19 Immunity Test

Merck and Ridgeback Biotherapeutics' oral antiviral medication reduced the risk of hospitalization or death from COVID-19 by 50% relative to placebo in a Phase III clinical study.

Merck and Ridgeback Biotherapeutics’ Oral Antiviral COVID-19 Treatment Reduces Risk of Hospitalization or Death by 50%

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Reformulation strategies are useful tools for more than just stretching out the potential return on investment for a product.

Considering Bio/Pharma Reformulation Strategies

Appili Therapeutics and AiPharma Global Holdings announced a strategic alliance to advance the global development of a broad-spectrum antiviral treatment in oral tablet form for the treatment of COVID-19.

Antiviral Oral Medicine Emerges as Potential COVID-19 Treatment and Companies Make Strategic Alliance

Rengeron’s trial found that REGEN-COV significantly reduced viral load of patients with COVID-19.

REGEN-COV Shows Promising Results in Hospitalized COVID-19 Patients

EMA's CHMP is going to perform an accelerated assessment of data submitted by Moderna regarding the use of a booster dose of Spikevax. 

COVID-19 Update

Combatting Future Viral Threats with Vaccine Advances

What’s Next for COVID-19 Vaccines and Variants?

Key Elements for Assay Transfer Success